Drug Discovery@nature.com 9 August 2013

Advertisement Final Agenda Now Available for CDI's 2013 User Group Meeting! Keynote by Dr. Leroy Hood, 2011 National Medal of Science recipient Data-driven, iPSC-based scientific talks by pharma, academic & biotech researchers CDI tour, welcome reception, session breaks & dinner/social event to network Register now! Special discount to first 100 registrants TABLE OF CONTENTS 9 August 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Immunology  FOCUS ON MICROBIOTA This series of specially commissioned articles discuss the reciprocal regulation between the host immune system and commensal microbiota, the dynamic interactions between commensals and pathogens, and emerging information on how resident viruses might influence immune homeostasis.    News Top Synthetic molecule chokes TB growth doi:10.1038/nature.2013.13500 Compound acts by novel mechanism and is effective in mice. Full Text US National Cancer Institute's new Ras project targets an old foe doi:10.1038/nm0813-949 A new initiative hopes to succeed where many have failed: to target the 'undruggable' oncogene, RAS. Full Text Engineered mice act as hepatitis C model doi:10.1038/nature.2013.13477 Rodents may eventually replace chimpanzees in vaccine research. Full Text Bacteria-killing dispute casts doubt on antibiotic development doi:10.1038/nm0813-954 A unified mechanism of antibiotic action based on the production of reactive oxygen species is under attack. Full Text Analysis Top Connecting the microbiome to obesity-associated cancers doi:10.1038/scibx.2013.743 Researchers have described a pathway that shows how obesity-associated changes in the gut microbiome could lead to liver cancer. The findings lay a foundation for developing new microbiome-targeted diagnostics to identify at-risk individuals and intervention strategies. Full Text Novelty in the target landscape of the pharmaceutical industry doi:10.1038/nrd4089 An analysis of the overlap in the drug targets that are being pursued across the industry indicates that more than half of the novel drug targets in current pipelines are being pursued by only one company. Full Text Research Highlights Top Mood disorders: Room for improvement doi:10.1038/nrd4078 Two independent studies shed light on the mechanism of action of commonly prescribed antidepressants and suggest new therapeutic targets. Full Text G protein-coupled receptors: Two landmark class B GPCR structures unveiled doi:10.1038/nrd4082 High-resolution crystal structures of the human corticotropin-releasing factor 1 (CRF1) receptor and the human glucagon receptor are reported in Nature. Full Text Influenza: Viral vector delivers protective antibodies doi:10.1038/nrd4079 Vectored immunoprophylaxis durably protects even immunocompromised mice from illness caused by diverse influenza strains. Full Text Research & Reviews Top Validating therapeutic targets through human genetics doi:10.1038/nrd4051 Many clinical trial failures can be traced back to the limited predictive value of preclinical models of disease. This Review discusses how knowledge from human genetics can be used as a tool to more effectively prioritize molecular targets in drug development. Full Text Gene-engineered T cells for cancer therapy doi:10.1038/nrc3565 Adoptive T cell therapy using engineered T cells to improve antitumour responses is showing promise for the treatment of haematological malignancies in particular. This Review discusses the strategies and progress being made to engineer T cells to treat cancer patients. Full Text Bringing genome-wide association findings into clinical use doi:10.1038/nrg3523 Despite the impact of genome-wide association studies (GWASs) on disease genetics, there has been scepticism about their usefulness in clinical translation. This Review highlights pertinent examples in which clinical application has been achieved and considers the wider potential for translation. Full Text Applications of nanotechnology for immunology doi:10.1038/nri3488 This Review describes how the unique properties of different nanostructures can be used to either enhance or to suppress immune responses, and discusses the promise of these strategies for developing more effective immunotherapies. Full Text Drug Discovery JOBS of the week Postdoctoral Fellow in Biomaterials and Drug Delivery Vanderbilt University Research Associate II Oncology Drug Discovery, Biology Johnson & Johnson PhD project on lncRNA role in cancer drug activity University of Rennes 1 PhD in Biomedical Engineering: Ultrasound for Drug Delivery University of Glasgow Postdoctoral Position in Molecular Biology and Drug Discovery Moffitt Cancer Center & Research Institute More Science jobs from Drug Discovery EVENT Resources for Computational Drug Discovery 09.12.13 Cambridge, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.